Loading patent…
AssigneeThe Boards of Regents of the University of Oklahoma
InventorMartin Levine
Estimating the term…
The present invention is directed to mutants of lysine decarboxylase, nucleic acids encoding the mutants, and vaccines comprising the mutants for inhibiting and reducing the development of periodontal diseases, including gingivitis and chronic periodontitis. The vaccine composition comprises a recombinant lysine decarboxylase mutant which is based on a native version of the enzyme from E. corrodens and induces production of antibodies that inhibit the activity of the lysine decarboxylase enzyme in the oral cavity. The recombinant lysine decarboxylase mutant, in one version, comprises a mutation at residue 365 or at other locations within the active site, and in a preferred embodiment is produced from E. coli in large amounts and to form inclusion bodies. The purified inclusion bodies can then be used in the vaccine composition to induce in vivo production of antibodies that inhibit the activity of native E. corrodens lysine decarboxylase.
An isolated lysine decarboxylase mutant comprising a substitution at a position corresponding to position 365 of SEQ ID NO:2, wherein said mutant has at least 95% sequence identity to SEQ ID NO:2 and has diminished lysine decarboxylase activity.
An isolated polypeptide having at least 95% amino acid sequence identity to the amino acid sequence of the polypeptide having SEQ ID NO:2, the isolated polypeptide having an amino acid substitution corresponding to position 365 of SEQ ID NO:2.
An isolated nucleic acid sequence comprising or complementary to a nucleotide sequence encoding a mutant of SEQ ID NO:2 wherein the mutant comprises a substitution at a position corresponding to position 365 of SEQ ID NO:2, and wherein the mutant has at least 95% identity to SEQ ID NO:2, the mutant having lysine decarboxylase activity which is diminished in comparison to that of the lysine decarboxylase having SEQ ID NO:2.
Dependencies are inferred from the claim text.